Shares of Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF – Get Free Report) were up 1.7% on Tuesday . The stock traded as high as $1.20 and last traded at $1.19. Approximately 10,036 shares were traded during trading, a decline of 44% from the average daily volume of 17,766 shares. The stock had previously closed at $1.17.
Medexus Pharmaceuticals Stock Performance
The company’s 50-day moving average is $1.21 and its 200-day moving average is $1.39.
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Read More
- Five stocks we like better than Medexus Pharmaceuticals
- Low PE Growth Stocks: Unlocking Investment Opportunities
- What is a Short Call Butterfly Spread? Explanation with Examples
- Top Stocks Investing in 5G Technology
- First Quarter Wrap-Up Reveals Retail’s Shifting Sands
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Williams-Sonoma Stock Forecast to Hit $500? Here’s How
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
